FDA approves Horizant to treat restless legs syndrome On April
FDA approves Horizant to treat restless legs syndrome
On April 6, the U.S. Food and Drug Administration approved Horizant Extended Release Tablets (gabapentin enacarbil), a once-daily treatment for moderate-to-severe restless legs syndrome (RLS).